Clinical Trial

Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions

Name: Bioequivalence Study of EMPAGLIFLOZIN (25 mg Tablets) vs. JARDIANCE® (25 mg Tablets), in Healthy Research Subjects, Under Fasting Conditions — clinical trial record (NCT07479108)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EB-24-003

Completed

View on ClinicalTrials.gov →

Summary

Prospective, longitudinal, single-dose, randomized, open-label, crossover 2x2, two treatments, two periods, two sequences controlled clinical study

Trial Details

NCT Number	NCT07479108
Lead Sponsor	ADIUM
Conditions	Bioequivalance
Enrollment	32 participants
Start Date	2024-11-29
Primary Completion	2024-12-11 (estimated)
Study Completion	2024-12-11 (estimated)
Updated on ClinicalTrials.gov	2026-03-18